LAUSR

Abstract Background We comprehensively evaluate the efficacy and safety of US-guided radiofrequency ablation (RFA) in the treatment of papillary thyroid microcarcinoma (PTMC) via a systematic review and meta-analysis. Methods We searched the PubMed, Embase and Cochrane Library databases for studies published during the time between the establishment of the database through October 2021. We included a 10 non-randomized controlled trial (non-RCT) that reported the application of US-guided RFA in PTMC. The sample size of patients totaled 1279. We evaluated the ablation efficacy by analyzing the volume reduction rate (VRR), complete disappearance rate (CDR) and recurrence rate of PTMC treated by RFA. We analyzed all data using STATA version 15.1 (Stata Corporation, College Station, TX). Results Our pooled results proved RFA treatment significantly reduces the volume of tumors (Weighted Mean Difference [WMD] = −103.20, 95% CI: −111.93 – −94.48, p = 0.000). We also found the VRR at 12 months after RFA was 93.27% (95% CI: 84.68–101.86), and the CDR at 12 months after RFA was 64% (95% CI: 39–89%). Additionally, pooled results showed the incidence of mPTC residue in ablation area, newly discovered mPTC and lymph node metastases after RFA treatment were respectively 0.3% (95% CI: −0.1–0.7%), 2.5% (95% CI: 1.1–3.9%) and 1.0% (95% CI: 0.2–1.9%), and the incidence of complications after RFA treatment was 1.8% (95% CI: 0.7–3.2%). Conclusions US-guided RFA is effective and safe for treating PTMC. It could be an excellent alternative to the existing treatment options.